Clinical Trial

Canadian Profiling and Targeted Agent Utilization Trial

Study Description

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Olaparib

300mg taken twice daily

Drug - Dasatinib

100mg administered orally once daily

Drug - Nivolumab plus Ipilimumab

Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks.

Drug - Axitinib

5mg orally twice daily

Drug - Bosutinib

500mg orally once daily

Drug - Crizotinib

250mg orally twice daily

Drug - Palbociclib

125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days

Drug - Sunitinib

50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off

Drug - Temsirolimus

25mg infused over a 30-60 minute period once a week

Drug - Erlotinib

150mg orally, once daily

Drug - Trastuzumab plus Pertuzumab

Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes.

Drug - Vemurafenib plus Cobimetinib

Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest

Drug - Vismodegib

150mg taken orally, once daily

Additional Information

Official Study Title

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial

Clinical Trial ID

NCT03297606

ParticipAid ID

qaQM7a